Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. VIZAMYL (flutémétamol, 18F)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

VIZAMYL (flutémétamol, 18F)

Medicine - Posted on Jul 18 2022
Active substance (DCI)
  • flutémétamol (18F)
history (2)
  • 6/8/22

    VIZAMYL (flutémétamol,18F) - produit diagnostique de la maladie d’Alzheimer

    Key points Favourable opinion for reimbursement for Positron Emission Tomography (PET) imaging in the diagnosis of Alzheimer...
    CAV :
    54321
    icône flèche
  • 3/22/17

    VIZAMYL (flutemetamol, 18F), diagnostic product for the central nervous system

    Insufficient actual benefit in the absence of any role in the diagnostic strategy for dementia VIZAMYL is a radiopharmaceuti...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • V09AX04
Manufacturer
GE HEALTHCARE SAS
Presentation

VIZAMYL 400 MBq/ml, solution injectable (code CIS : 67652999)
1 flacon(s) en verre de 10 ml - (Code CIP : 34009 550 001 9 8)
1 flacon(s) en verre de 15 ml - (Code CIP : 34009 550 002 0 4)

All our publications
    Alzheimer’s disease and mental disorders Central nervous system diseases Drug therapy Geriatrics Medical imaging Neurodegenerative diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
2y0uWmumsQYYvYMD